Aviceda Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aviceda Therapeutics's estimated annual revenue is currently $4.3M per year.(i)
  • Aviceda Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Aviceda Therapeutics has 28 Employees.(i)
  • Aviceda Therapeutics grew their employee count by 8% last year.

Aviceda Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder, CEO & President, Executive Board DirectorReveal Email/Phone
2
Scientific Co-FounderReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Chief Clinician and Scientist OncologyReveal Email/Phone
6
Chief Development Officer & SVPReveal Email/Phone
7
Director, Nanoparticle Formulations and Analytical Development (CMC-Head)Reveal Email/Phone
8
Senior Director / Head BiologyReveal Email/Phone
9
Executive Assistant; Office ManagerReveal Email/Phone
10
Senior Research Associate / Lab ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Aviceda Therapeutics?

Aviceda Therapeutics is a late-stage, pre-clinical stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, oncologic, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Aviceda’s platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$4.3M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M288%N/A
#2
$2.8M28N/AN/A
#3
$4M28N/AN/A
#4
$2.7M28N/AN/A
#5
$2.8M28N/AN/A